AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03511482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lloyds Pharmacy Online Doctor
Description: Online Doctor is part of Expert Health Ltd a doctor-led initiative providing safe and reliable remote online healthcare to adults in the UK. Their patient-centred model of healthcare allows patients to tailor care around their schedule and increases healthcare access for harder-to-reach patient groups.~As the first ever online healthcare organisation to register with the government regulator of healthcare - and having received outstanding feedback from the Care Quality Commission about the high level of safe, effective, caring, responsive and well led care provided by the service - They pride themselves on their pioneer status and work constantly to expand the boundaries of personalised healthcare.
Study NCT02709070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection
Description: hepatectomy for HCC
Study NCT02709070 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resection
Description: hepatectomy for HCC
Study NCT02709070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: highly-purified CTL
Description: hepatectomy first, followed by highly-purified CTL treatment
Study NCT03509948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisine
Description: cytisine 1.5 mg film-coated tablets
Study NCT03519230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib capsule
Description: 60 mg twice daily (BID), orally (per os-PO)
Study NCT03519230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: 60mg BID, PO
Study NCT04208412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: KVD900 tablet 600 mg
Study NCT04208412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: KVD900-matched Placebo Tablet
Study NCT04211688 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Schema therapy
Description: Bimonthly outpatient psychotherapy delivered in individual setting
Study NCT04177173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Description: improvement of disease activity
Study NCT04177173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate 10 mg
Description: improvement of disease activity
Study NCT04177173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate 10 mg
Description: improvement of disease activity
Study NCT03300726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CSF analysis
Description: CSF analysis for tau, p-tau181, Abeta42, and CSF levels of markers of synaptic injury
Study NCT04211688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Schema therapy
Description: weekly outpatient psychotherapy delivered in group setting
Study NCT01900769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blood Volume Dilution
Study NCT01320995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineal ultrasound
Description: Perineal ultrasound is performed after delivery in order to better detect sphincter lesions.
Study NCT02851628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternative sizing model based trial mask
Description: A trial full face mask to be used for this trial for the treatment of obstructive sleep apnea using CPAP therapy.
Study NCT02791009 — intervention group
Intervention type: OTHER
Intervention: Electrocardiogram (ECG)
Description: ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
Study NCT02851628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype Full Face Mask
Description: A prototype full face mask with previous clinical trial experience used for the treatment of obstructive sleep apnea using CPAP therapy.
Study NCT02155127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking
Study NCT03300726 — intervention group
Intervention type: RADIATION
Intervention: Functional MRI
Description: Functional MRI during resting state and semantic memory task activation
Study NCT01588678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3078a
Description: DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
Study NCT03347929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen 500 Mg
Description: 10 days treatment with Naproxen 500 mg twice daily
Study NCT03347929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 days treatment with Placebo1 tablet twice daily
Study NCT03080272 — intervention group
Intervention type: OTHER
Intervention: no intervention will take place
Description: Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place
Study NCT03069365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Description: Film-coated tablet
Study NCT03540446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: First Relief Treatment
Description: To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.
Study NCT02791009 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
Study NCT02791009 — intervention group
Intervention type: OTHER
Intervention: Clinical Assessment
Description: Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
Study NCT02791009 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular Ultrasound (CVUS)
Description: To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
Study NCT02791009 — intervention group
Intervention type: OTHER
Intervention: Cognitive Test
Description: To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
Study NCT02384837 — intervention group
Intervention type: DEVICE
Intervention: EXCEL biodegradable polymer-coated sirolimus-eluting stent
Study NCT01644461 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Autologous Human Platelet Lysate
Description: All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
Study NCT04317547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steering Teens Safe (STS)
Description: The goal of STS is to provide intervention parents with guidance and communication skills, which will enable parents to effectively communicate with their teens about specific driving safety topics (e.g., speeding, seatbelt use, distracted driving). Our proposed parent training has two components: an individualized virtual communication training (provided to parents via Skype by a trained research team member) and a parent-teen safe driving communication guide (available online).
Study NCT04317547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Driving Feedback Technology.
Description: The driving feedback technology will include the Azūga™ in-vehicle device and smartphone app.
Study NCT02594384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAM-002A
Description: 25 mg capsules or 50 mg capsules
Study NCT02594384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein
Study NCT02594384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg by vein
Study NCT02001285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.
Study NCT02001285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.
Study NCT03845855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: Virtual reality with a game
Study NCT03845855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: robotic gait
Description: robotic gait therapy
Study NCT03845855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robotic gait
Description: robotic gait therapy
Study NCT00331604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, inhalation.
Study NCT00331604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Injection s.c., 50% of daily dose.
Study NCT00331604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Injection s.c., 50% of daily dose.
Study NCT00331604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target dose titration scheme, injection s.c.
Study NCT00331604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target dose titration scheme, injection s.c. After 2 years.
Study NCT03858920 — intervention group
Intervention type: DEVICE
Intervention: Fibroscan of Liver
Description: A non-invasive diagnostic device used to measure liver scarring
Study NCT03858920 — intervention group
Intervention type: PROCEDURE
Intervention: Low-dose non-contrast CT
Description: CT scan as part of routine research care
Study NCT03635021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: oxaliplatin 85 mg/m2 administered by IV infusion over 120 minutes on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46- 48 hours on Days 1 and 2
Study NCT03635021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg administered by intravenous (IV) infusion over 60 minutes on Day 1 of each 14-day cycle
Study NCT03635021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg administered by IV infusion over 60 minutes on Day 1 of each 14-day cycle
Study NCT03635021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: irinotecan 180 mg/m2 administered as a 90 minutes IV infusion on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46-48 hours on Days 1 and 2
Study NCT03829020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC
Study NCT03829020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO
Study NCT03829020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir Mesylate
Description: Given PO
Study NCT02556528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Study NCT01146886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 135585
Description: Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on on placebo) on Day 1
Study NCT01146886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 135585
Description: Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on placebo) on Day 1; Part 2 - oral doses given to 12 subjects on Day 1
Study NCT03425331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
Study NCT03425331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
Study NCT03438474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical procedure for endometrial cancer
Description: total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)
Study NCT03438474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard surgical procedure for endometrial cancer
Description: total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)
Study NCT03438474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: systematic lymphadenectomy (LNE)
Description: systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels
Study NCT01360021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort
Description: Breath actuated metered dose inhaler
Study NCT01360021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort
Description: Actuation counter pressured metered dose inhaler
Study NCT01360021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Actuation counter pressured metered dose inhaler
Study NCT03972709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galegenimab
Description: Intravitreal (ITV) injections of galegenimab
Study NCT03972709 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Sham control
Study NCT02714140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PB-HCT +
Description: Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all EXISTING HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
Study NCT02714140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PB-HCT -
Description: Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and select 3 PB-HCT options that are less preferred than the common option
Study NCT02778204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 8 mg/kg oral solution as a single dose.
Study NCT02778204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 8 mg/kg oral solution given twice daily.
Study NCT04662307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent cardiopulmonary rehabilitation system (ICRS)
Description: Participants are required to wear a wristband heart rate monitor and exercise on a cycling ergometer-based ICRS for 30 minutes (5 minute of warm-up, 20 minutes of training followed by 5 minutes of cooldown). The target intensity for the 20-min training period is set at 60%\~80% HRR determined in the pretest of cardiopulmonary exercise test.
Study NCT01985737 — intervention group
Intervention type: OTHER
Intervention: Sample collection
Study NCT02422030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor Tab. 40mg
Study NCT00432926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EDGE counseling, no maintenance
Description: Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
Study NCT02714140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Economic incentive
Description: Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.
Study NCT00432926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EDGE counseling, plus maintenance
Description: Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
Study NCT00432926 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
Study NCT02714140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Economic incentive
Description: Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.
Study NCT03514732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MELATONIN (MELATL07959)
Description: Pharmaceutical form:Capsule Route of administration: Oral
Study NCT03818113 — intervention group
Intervention type: OTHER
Intervention: cardioplegia with HTK-Bretschneider cardioplegic solution
Description: cardioplegia with HTK-Bretschneider cardioplegic solution
Study NCT03818113 — intervention group
Intervention type: OTHER
Intervention: cardioplegia with St. Thomas cardioplegic solution
Description: cardioplegia with St. Thomas cardioplegic solution
Study NCT00576719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive panic control treatment without parent involvement
Description: Intensive panic control treatment without parent involvement is an 8-day, intensive form of cognitive behavioral therapy (CBT) with exposure, including 15-20 hours of direct therapist contact. The basic treatment components are psychoeducation about anxiety, restructuring anxiety-provoking thoughts, exposure to bodily sensations that trigger panic, and in vivo exposures.
Study NCT00576719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive panic control treatment with parent involvement
Description: Intensive panic control treatment with parent involvement involves the same form of intensive CBT, but with direct parent involvement. Parents will attend the last 30 minutes of didactic sessions, complete homework assignments, learn ways to coach their children, and participate in selected exposures.
Study NCT00576719 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist control
Description: Waitlist control participants will receive active treatment (treatment with or without family involvement) after 6 weeks of waitlist.
Study NCT02828579 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Laparoscopic Sleeve Gastrectomy (LSG) Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
Study NCT00722228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous or Allogeneic tumor cells
Description: Five vaccine doses, injected subcutaneously at 3-week intervals. Each dose is composed of irradiated and DNP-conjugated tumor cells.
Study NCT00626002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: 100mg ABT-874 administered SQ every 4 wks for approximately 204 weeks
Study NCT02714140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PB-HCT ++
Description: Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible ENHANCED HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
Study NCT02714140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Reminder
Description: Participants will receive an SMS reminder to test.
Study NCT02714140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS Reminder
Description: Participants will receive an SMS reminder to test.
Study NCT01054469 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP block placement with placebo
Description: 20 ml of normal saline (placebo)
Study NCT01054469 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of block with ropivacaine
Description: 20 ml of 0.5% ropivacaine hydrochloride
Study NCT01243866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comprehensive dental treatment
Description: Early treatment children were scheduled for comprehensive dental treatment over a 2-month period (from May to June 2007). All test children had their last dental treatment visit within the last 2 weeks of the second treatment month. The follow-up survey was scheduled for each child to be approximately 6-month after their dental last visit. This step was very important to make sure that all children were examined at exactly the same interval between end of treatment and when re-examined at the follow-up examination.
Study NCT01243866 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Only emergency dental treatment
Description: Regular treatment did not receive any dental treatment in the period when the early children were treated unless they had toothache or dental infection. In that case they were treated for the pain but did not have comprehensive dental treatment